Inclusion Criteria:~1. The Sponsor will rely on NIA-AA Alzheimer's Disease Diagnostic Guidelines for Early
Symptomatic Alzheimer's Disease (AD) with a 20-30 MMSE score, Clinical Dementia Rating (CDR) global score of
0.5 or 1, and impaired memory performance below an education adjusted cut-off score on the Logical Memory II
subscale delayed paragraph recall (LM-IIa) of the Wechsler Memory Scale- Revised (WMS-R) (127) (≥16 years: ≤8;
8-15 years: ≤4; 0-7 years: ≤2).~2. Age between 60 and 85 years (inclusive).~3. Good general health with no
disease likely to interfere with the study assessments.~4. On a stable medication regimen for eight weeks prior
to the study and is anticipated to remain stable during the study.~5. Subject is not pregnant, lactating, or of
childbearing potential (i.e., women must be two years post-menopausal or surgically sterile). If a woman is of
childbearing potential, her partner must use barrier contraception throughout the study.~6. Amyloid-positive
PET scan (performed only if the subject meets all other inclusion criteria). An amyloid-positive PET scan is
classified by an SUVR composite score cutoff of 1.18 units. Prior evidence of amyloid positivity by PET or CSF
will also be accepted for eligibility.~7. Ability to understand and provide informed consent.~8. Has
availability of a study partner who has regular contact with the participant and knows him/her well.~
